Astrazeneca (NYSE:AZN) followed Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) this morning by delivering a disappointing performance from its SGLT-2 inhibitor Farxiga. The drug belongs to a class that is widely projected to become the fastest growing among diabetes medicines (see tables below).
As such, weak first-quarter sales from the main players is worrying, and the blame is being laid at the feet of US pricing pressures. Diabetes is an area where payers have successfully flexed their muscles. However, it seems that another factor is playing a role: the message that this class can reduce a patient's risks from heart disease is taking time to have an impact.
Astrazeneca said growing intra-class competition and the impact of affordability programmes and managed-care access subdued Farxiga growth in the US, where sales inched only 2% higher, to $96m, in the first quarter.
J&J painted an even worse picture with Invokana - lower prices caused US sales of the medicine to fall 13% on the same quarter of last year. The company also blamed increasing discounts for managed care and a higher composition of Medicaid sales, where prices are typically lower.
The Lilly result was probably the most surprising given that the company has been heavily marketing Jardiance's success in its cardiovascular outcome study since January. New patient starts have surged 75% since the company was allowed to begin marketing on evidence that the drug can reduce the risks of death and complications from heart disease, the company said this week. However revenues still came in lower than the sell-side was expecting.
Lilly and partner Boehringer Ingelheim are the only companies allowed to actively market a cardiac benefit for their SGLT2, although big studies are due to report on Invokana and Farxiga in the next couple of years. These are widely expected to confirm a class effect, helping to drive use of all of these medicines (ACC - Jardiance heart benefit looks like a class effect, March 20, 2017).
However, the finding represents a big philosophical shift for this area of medicine, which is more used to dealing with the discovery of safety signals.
"We have to remember we are talking about changing very well entrenched treatment practises and physicians do take some time to get comfortable with new drugs and new classes," said Mark Mallon, head of Astrazeneca's global product strategy and medical affairs, in a media call this morning. "They need to see the data and the data is absolutely coming. But it's going to take time to build that up."
Assuming the class effect is confirmed, having three companies actively promoting a cardiac benefit will surely help drive uptake. However another issue is bringing cardiologists on board - endocrinologists and primary care doctors are currently the main prescribers of these drugs - an issue that Lilly executives have said they are closely monitoring.
"Cardiologists, in the case of Jardiance, are a significant source of authority. And while we have seen an increase, the base of prescribing is extremely, extremely small," Enrique Conterno, head of Lilly's diabetes business, told analysts on a call last week.
Merging therapy areas
The discovery of cardioprotective benefits for the SGLT2s and to a lesser extent the GLP-1 agonists points to a merging of therapy areas that looks set to become only more apparent in the coming years.
Novo Nordisk (NYSE:NVO) has already won approval for Victoza as an obesity therapy. Astrazeneca this year started two outcome trials with Farxiga in heart failure and chronic kidney disease, which will recruit both diabetic and non-diabetic patients. And its blood thinner Brilinta is being trialed in diabetic patients in the huge Themis study, to see if it can reduce the risk of heart attack and stroke.
The UK pharma giant has even merged its cardiovascular and diabetes drugs into a single reporting unit, which chief executive Pascal Soriot put down to more and more overlap.
"We believe there are substantial synergies across those therapy areas - operationally in the field but also from a medical view point," he told journalists earlier today.
A cynic might also see the move as a convenient way to de-emphasise Brilinta, sales of which have long disappointed.
However it is readily apparent that the SGLT2s have the potential to steer the treatment of diabetics closer to the cardiovascular world than ever before. The extent to which these drugs will be embraced by cardiologists is hard to foresee until more trials report, but could have a huge impact on the commercial potential of the class.
More:
Calling All Heart Docs - Your Diabetes Drugs Need You - Seeking Alpha
- This 'itchy' symptom is an early sign of diabetes that people often miss; know more about it - The Times of India - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - ABC News - February 7th, 2025
- Incidence of type 2 diabetes and metabolic syndrome by Occupation 10-Year follow-up of the Gutenberg Health Study - BMC Public Health - February 7th, 2025
- Abbotts Above the Bias Film Reveals Misconceptions Can Impact Diabetes Care - MultiVu - February 7th, 2025
- Q&A: Diabetes care for the aging population in the digital age - Medical Xpress - February 7th, 2025
- The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes - Nature.com - February 7th, 2025
- Nanoparticle Therapy has Potential to Reprogram the Immune System in Type 1 Diabetes - Managed Healthcare Executive - February 7th, 2025
- Muscle quality index is correlated with insulin resistance and type 2 diabetes mellitus: a cross-sectional population-based study - BMC Public Health - February 7th, 2025
- Assessing type-2 diabetes risk based on the Indian diabetes risk score among adults aged 45 and above in India - Nature.com - February 7th, 2025
- Single-cell atlas of human pancreatic islet and acinar endothelial cells in health and diabetes - Nature.com - February 7th, 2025
- Sugary Drinks Fuel Millions of Diabetes and CVD Cases - Medscape - February 7th, 2025
- 1 in 5 UK adults estimated to have diabetes in new record high - Euronews - February 7th, 2025
- New, increasingly widely used diabetes medication may have additional health benefits for older adults - Medical Xpress - February 7th, 2025
- Patients using diabetes apps can miss critical alerts. Heres how to make sure youre getting them - Canon City Daily Record - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - News-Press Now - February 7th, 2025
- Does wearing a continuous glucose monitor help people without diabetes? We asked experts. - Popular Science - February 7th, 2025
- What is prediabetes and what can you do to stop it? - The Independent - February 7th, 2025
- Diabetes symptoms: 6 high blood sugar warning signs that show on hand and feet - India.com - February 7th, 2025
- The #1 Habit for Better Heart Health If You Have Diabetes, According to Experts - EatingWell - February 7th, 2025
- 'Fix Broken Food System!' Government Urged as Study Says 1 in 5 Brits Affected by Diabetes - Men's Health UK - February 7th, 2025
- World Diabetes Day 2024 - World Health Organization (WHO) - December 6th, 2024
- The WHO Global Diabetes Compact - December 6th, 2024
- Diabetes - World Health Organization (WHO) - December 6th, 2024
- Kumamoto University researchers discover groundbreaking antidiabetic compound - EurekAlert - December 6th, 2024
- Med's David Kaelber comments on GLP-1 agonists, which provide benefits like managing diabetes and weight loss - The Daily | Case Western Reserve... - December 6th, 2024
- Jordan Chiles Is On a Mission To Raise Awareness for Early Type 1 Diabetes Screening - Verywell Health - December 6th, 2024
- There's A Tasty Food That May Reduce Your Risk Of Developing Type 2 Diabetes, Study Shows - HuffPost - December 6th, 2024
- Empagliflozin Linked to Lower Risk of Diabetic Retinopathy Progression - Medpage Today - December 6th, 2024
- GLP-1 Medications Associated with Reduced Likelihood of Dementia Compared to Other Diabetic Meds - Epic Research - December 6th, 2024
- Sanders Slams Greed That Led to Surge in Obesity, Diabetes in US - The Well News - December 6th, 2024
- Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments - The Wall Street Journal - December 6th, 2024
- New Study Teases Out Chocolate and Diabetes Connection - Medpage Today - December 6th, 2024
- Diabetes tool turned wellness trend: Is a glucose monitor right for you? - KARE11.com - December 6th, 2024
- Reporter doesnt have diabetes but wore a glucose monitor anyway. Here's what she learned - CNN - December 6th, 2024
- Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% - Investors |... - December 6th, 2024
- I dont have diabetes, but I wore a glucose monitor for six weeks. Heres what I learned about food (and anxiety) - CNN - December 6th, 2024
- Higher niacin levels linked to lower cardiovascular risk, but not in those with diabetes - Healio - December 6th, 2024
- This Type Of Chocolate Could Reduce Type 2 Diabetes Risk By 21% - NDTV - December 6th, 2024
- New Study Links Safer BPA Alternatives to Obesity, Diabetes, and Hormone Disruption - SciTechDaily - December 6th, 2024
- Turns Out Dark Chocolate Has a Health Benefit That's Shockingly GreatAnd Totally Unexpected - Well+Good - December 6th, 2024
- Global report on diabetes - World Health Organization (WHO) - October 22nd, 2024
- Ultra-processed food may be particularly harmful for people with diabetes, scientists warn - The Independent - October 22nd, 2024
- New drugs may be able to treat multiple problems beyond diabetes - The Straits Times - October 22nd, 2024
- Best Fruits for Diabetes (and What To Avoid) - Health Essentials - October 22nd, 2024
- Cutting Sugar May Reduce Your Diabetes, Stroke, and Depression Risk - Healthline - October 22nd, 2024
- Can Diabetes Care Teams Improve Patient Outcomes and Value? - Medscape - October 22nd, 2024
- Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD - MD Magazine - October 22nd, 2024
- High expression of CNOT6L contributes to the negative development of type 2 diabetes - Nature.com - October 22nd, 2024
- Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic... - October 22nd, 2024
- Dental teams could detect undiagnosed diabetes in more than one million people with new care pathway - Nature.com - October 22nd, 2024
- Groundbreaking Innovations in Diabetes Care: Highlights from the 2024 Diabetes Technology Meeting - Beyond Type 1 - October 22nd, 2024
- COVID-19 linked to type 2 diabetes onset in children - Medical Xpress - October 22nd, 2024
- The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel... - October 22nd, 2024
- Does microdosing Ozempic work? What experts are saying about the diabetes drug also used for weight loss - Medical Xpress - October 22nd, 2024
- The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024 - Managed Healthcare Executive - October 22nd, 2024
- The overexpression of human amylin in pancreatic cells facilitate the appearance of amylin aggregates in the kidney contributing to diabetic... - October 22nd, 2024
- RNAO releases updated guidelines for diabetic foot ulcer care - Benefits and Pensions Monitor - October 22nd, 2024
- COVID-19 raises the risk of type 2 diabetes in children, study reveals - News-Medical.Net - October 22nd, 2024
- Semaglutide: What impact does it really have on heart health? - Medical News Today - October 22nd, 2024
- Glucose monitors for diabetes have finally been funded but a chronic workforce shortage will limit the benefits - The Conversation - October 22nd, 2024
- Early vs Late Fast Window: Is One More Effective? - Medscape - September 13th, 2024
- Breakthrough T1D Walk to Cure Type 1 Diabetes - KATU - September 13th, 2024
- Foods That May Increase Kids' Risk of Type 1 Diabetes Revealed - Newsweek - September 13th, 2024
- Beds and Herts patients to be re-tested in diabetes results error - BBC.com - September 13th, 2024
- This common habit increases your diabetes risk by 50%; Heres how to fix it - The Economic Times - September 13th, 2024
- Elevated risk of pre-diabetes and diabetes in people with past history of COVID-19 in northeastern Nigeria - BMC Public Health - September 13th, 2024
- Study links bananas, oats and yoghurt to greater diabetes risk in susceptible children - The Guardian - September 13th, 2024
- Could the Norton research teams studying diabetes and Alzheimer's come up with a cure? - Courier Journal - September 13th, 2024
- Weight loss, better beta-cell function tied to long-term glycemic control with tirzepatide - Healio - September 13th, 2024
- Study finds weekly insulin injections as effective for diabetes as daily shots - UPI News - September 13th, 2024
- Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Heres what the science says - The Conversation - September 13th, 2024
- With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes - PR Newswire - September 13th, 2024
- Dining with Diabetes workshops offered - The Courier-Express - September 13th, 2024
- Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing - News-Medical.Net - September 13th, 2024
- The menopause can increase your likelihood of developing heart disease, type 2 diabetes and hypertension but exercise can help lower risk - The... - September 13th, 2024
- Artificial pancreas shows promise in people with type 1 diabetes on kidney dialysis - MSN - September 13th, 2024
- How an Indian executive battled flesh-eating disease and diabetes, and won - South China Morning Post - September 13th, 2024
- India brings early Diabetic Retinopathy detection to the last mile with Artificial Intelligence - PR Newswire - September 13th, 2024
- Why this diabetes drug may be the answer to NASA search for radiation protection - Texas Public Radio - September 13th, 2024
- The National Association of Chain Drug Stores and the American Diabetes Association Promote Nutrition Security and its Role in Preventing and Managing... - September 13th, 2024